Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr
News

Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr

Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025

  • By IPP Bureau | January 24, 2026

Jagsonpal Pharmaceuticals Ltd. has reported standalone financial results for the period ended December 31, 2025.

Jagsonpal Pharmaceuticals has posted net profit of Rs. 10.95 crore for the period ended December 31, 2025 as against net profit of Rs. 12.57 crore for the period ended September 30, 2025. The company has posted net profit of Rs. 31.99 crore for the period ended December 31, 2024.

Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025 as compared to Rs. 77.49 crore during the period ended September 30, 2025. The company reported total income of Rs. 76.34 crore during the period ended December 31, 2024.

For the 9 months period ended December 31, 2025, Jagsonpal Pharmaceuticals has reported total income of Rs. 231.84 crore as compared to Rs. 215.57 crore during the 9 months period ended December 31, 2024.

The company has posted net profit of Rs. 34.32 crore for the 9 months period ended December 31, 2025 as against net profit of Rs. 48.77 crore for the 9 months period ended December 31, 2024.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International